Lyme Disease Testing Market size is forecast to climb from USD 12.4 billion in 2025 to USD 27.27 billion by 2035, expanding at a CAGR of over 8.2% during 2026-2035. Industry revenue in 2026 is projected at USD 13.29 billion.
Growth Drivers & Challenge
The Lyme disease testing market is witnessing substantial growth globally, driven by the increasing prevalence of Lyme disease and the rising awareness regarding early diagnosis and treatment. One of the key growth drivers is the growing incidence of tick-borne diseases, particularly in North America and Europe, where climate change, deforestation, and expanding wildlife habitats have led to a higher population of ticks carrying the Borrelia burgdorferi bacterium. The rise in outdoor recreational activities and urbanization in previously forested regions has also contributed to the increased risk of tick exposure. As a result, healthcare providers and public health authorities are emphasizing early detection through reliable testing methods, which is significantly boosting the demand for advanced Lyme disease diagnostic solutions.
Another major driver propelling market growth is technological advancement in diagnostic tools. Traditional serological tests are being replaced or supplemented by molecular diagnostic methods such as PCR and next-generation sequencing, which provide higher sensitivity and specificity.
The development of rapid, point-of-care tests and multiplex assays that can detect multiple tick-borne pathogens simultaneously is transforming the diagnostic landscape. Furthermore, increased research funding, growing government initiatives to prevent vector-borne diseases, and the availability of advanced laboratory infrastructure are enhancing the adoption of innovative testing technologies across healthcare settings. However, a significant challenge faced by the Lyme disease testing market is the lack of standardization and the possibility of false negatives or false positives in current testing methods. The two-tier testing system, which includes enzyme immunoassay (EIA) followed by Western blot, sometimes fails to detect early-stage infections or leads to misdiagnosis due to variability in immune responses. Additionally, limited awareness in developing countries and the underreporting of cases due to poor surveillance systems hinder the global expansion of the market. Ensuring the accuracy and affordability of testing, especially in rural and low-resource areas, remains a persistent challenge for manufacturers and healthcare providers.
Request for a free sample report @
https://www.fundamentalbusinessinsights.com/request-sample/12986
Regional Analysis
North America
North America dominates the global Lyme disease testing market, primarily due to the high incidence of Lyme disease in the United States and Canada. The U.S. accounts for a majority of reported cases, particularly in the Northeast, Midwest, and Pacific Northwest regions, where tick populations are abundant. Public health campaigns and awareness programs by organizations such as the Centers for Disease Control and Prevention (CDC) have significantly boosted testing rates and early detection. The region also benefits from the presence of leading diagnostic companies and well-established healthcare infrastructure, enabling easy access to both conventional and advanced molecular testing methods. Moreover, growing investments in biotechnology research, favorable reimbursement policies, and the expansion of laboratory networks have strengthened market growth. The increasing use of home-based diagnostic kits and telemedicine for initial consultations is further supporting the expansion of Lyme disease testing services across the region.
Europe
Europe represents the second-largest market for Lyme disease testing, driven by the growing prevalence of the disease in countries such as Germany, the United Kingdom, Austria, and Sweden. The expansion of tick habitats due to changing climatic conditions has led to a significant increase in Lyme borreliosis cases across both rural and suburban areas. European governments are actively promoting public awareness and preventive measures through national surveillance programs and funding for diagnostic research. In addition, advances in laboratory automation, molecular diagnostics, and the integration of artificial intelligence in testing procedures are enhancing the accuracy and efficiency of Lyme disease detection. The presence of strong healthcare systems and favorable regulatory support for diagnostic innovation further contribute to regional growth. However, the market faces challenges related to diagnostic inconsistencies and the limited availability of specialized tests in certain regions, particularly in Eastern Europe. Ongoing research collaborations between public health institutes and diagnostic manufacturers are expected to mitigate these issues and improve test reliability.
Asia Pacific
The Asia Pacific region is emerging as a promising market for Lyme disease testing, driven by the increasing awareness of tick-borne diseases and growing healthcare investments. Countries such as China, Japan, and Australia are experiencing a rise in reported cases due to environmental changes and growing interaction between humans and tick habitats. Although the overall incidence of Lyme disease in Asia Pacific is lower than in Western countries, rising surveillance activities and diagnostic advancements are expected to stimulate market growth. The rapid expansion of healthcare infrastructure, improved access to molecular diagnostics, and growing adoption of point-of-care testing in rural areas are major contributors to market development. Governments and health organizations are increasingly focusing on vector control programs and public education to improve early disease detection. Despite these positive trends, low disease awareness, limited diagnostic coverage, and lack of standardized testing protocols in many developing countries remain obstacles to market expansion. Nonetheless, rising collaborations between local and international diagnostic firms are expected to strengthen regional capabilities over the coming years.
Browse complete report summary @
https://www.fundamentalbusinessinsights.com/industry-report/lyme-disease-testing-market-12986
Segmentation Analysis
Segments Analysis by Technology
Based on technology, the Lyme disease testing market is segmented into serological tests, molecular diagnostics, and other emerging technologies. Serological testing, including ELISA and Western blot, remains the most widely used method due to its availability and cost-effectiveness. However, molecular diagnostic methods such as PCR are gaining traction for their higher sensitivity and ability to detect Borrelia DNA directly from patient samples, particularly during early-stage infection. The integration of multiplex testing platforms and automation technologies is further enhancing diagnostic speed and precision.
Segments Analysis by Testing
By testing type, the market is divided into laboratory testing and point-of-care testing. Laboratory testing dominates the market due to its accuracy and widespread use in clinical and research settings. However, point-of-care testing is rapidly gaining momentum, especially in remote and underserved areas where access to laboratory facilities is limited. The growing demand for quick and convenient diagnostic solutions is encouraging companies to develop portable and easy-to-use testing kits capable of delivering reliable results in a shorter time frame.
Segments Analysis by Sample
In terms of sample type, the market is categorized into blood, cerebrospinal fluid (CSF), and others. Blood samples are the most commonly used due to ease of collection and their reliability for antibody-based testing methods. CSF testing is primarily utilized for diagnosing neuroborreliosis cases where the infection affects the central nervous system. With advancements in sample preparation and molecular detection, multi-sample approaches are being explored to enhance diagnostic accuracy and reduce false negatives, driving innovation across the global Lyme disease testing market.
Browse related reports @
https://www.fundamentalbusinessinsights.com/fr/industry-report/accounts-payable-automation-market-12985
https://www.fundamentalbusinessinsights.com/de/industry-report/dermaplaning-tools-market-12984
https://www.fundamentalbusinessinsights.com/it/industry-report/optical-interconnect-market-12983
https://www.fundamentalbusinessinsights.com/es/industry-report/tensiometer-market-12982
https://www.fundamentalbusinessinsights.com/ja/industry-report/macadamia-butter-market-12981
About Fundamental Business Insights:
Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.
Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email: sales@fundamentalbusinessinsights.com
